The Global mRNA Treatment market size is expected to grow at a compound annual growth rate (CAGR) of 21.2% from 2022 to 2030. The mRNA Treatment has various advantages, including vaccine preparation. mRNA is the biological preparation that induced active acquired immunity to a particular disease by stimulating the body’s immune system. Moreover, the advancement of lipid nanoparticle formulations for in vivo systemic delivery of mRNA fueling the development of in vivo transfection strategies.
The increasing prevalence of cancer, viral infections, and genetic disorders drive the mRNA treatment market. Additionally, raising awareness about vaccination fueling the global mRNA market. Furthermore, mRNA is being used to produce viral antigen proteins from within the cell are one of the promising therapies for viral disease. For instance, due to the outbreak of COVID-19 number of companies conducting clinical trials for vaccine development is projected to create lucrative opportunities in the near future. North America is dominating the market owing to the presence of key players in the region.
The Global mRNA Treatment market is segmented on the basis of product type, Therapeutic Area, Route of Administration, and region. Based on the product type, the market is divided into Prophylactic vaccines, Therapeutic vaccines, Therapeutic drugs. On the basis of Therapeutic Area, the market is divided into Infectious Diseases, Oncological Disorders, Other Disorders. On the basis of Route of Administration, the market is divided into Intravenous, Intramuscular, Intranasal, and Others. Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among that, Europe held the largest share of the market, followed by America and the Asia Pacific. On the other hand, North America is expected to dominate the market during the analysis of the forecast period.
The key players of this market include CureVac, Moderna, BioNTech (Pfizer), Translate Bio, Ethris (AstraZeneca), Kernal Biologics, Anima Biotech, H3 Biomedicine Inc., Arcturus Therapeutics, eFFECTOR Therapeutics, Inc., Ionis Pharmaceuticals, Inc., Stemirna Therapeutics Co., Ltd., Skyhawk Therapeutics, Inc., RNAimmune (Sirnaomics), Ziphius Therapeutics NV, miRagen Therapeutics, Inc., Silence Therapeutics, eTheRNA, Tiba Biotechnology, In-Cell-Art, Arcturus Therapeutics among others.